With Corlanor Approval, Amgen Kicks Its CV Push Into High Gear
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen will launch the heart failure drug within one week, creating a chance to build rapport with cardiologists ahead of potential launch of the PCSK9 blocker evolocumab later this year.
You may also be interested in...
Double-Jointed Partnership With Servier Could Jumpstart Amgen’s CV Portfolio
Amgen gets U.S. rights to a pair of heart failure candidates from the French firm, with the lead candidate already approved in Europe and likely to be filed quickly at FDA. Meanwhile, Servier obtains EU commercialization rights to a CV drug partnered between Amgen and Cytokinetics.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.